For the Inventor, By the Inventor

Enter assignee name

Ludwigshafen, Germany

Knoll Aktiengesellschaft

USPTO Granted Patents = 84

Trademarks = 1

Forward Citations = 1,217

Loading Chart...

Loading Chart...

147 inventors (with patents filed for the assignee):

Hermann Bujard (6 out of 27 patents)

Joerg Rosenberg (6 out of 34 patents)

Manfred Gossen (6 out of 20 patents)

4. Alan Martin Birch (6 out of 7 patents)

5. Bruce Jeremy Sargent (6 out of 10 patents)

6. Paul Rafferty (5 out of 22 patents)

7. Frank Kerrigan (4 out of 7 patents)

8. Heinz Einig (4 out of 8 patents)

9. David John Heal (4 out of 11 patents)

10. Paul Anthony Bradley (4 out of 5 patents)

11. Cynthia A Romerdahl (4 out of 12 patents)

12. Hans-Heinrich Gruenhagen (4 out of 4 patents)

13. Alan Smith (3 out of 21 patents)

14. Robert Brian Jones (3 out of 4 patents)

15. Sharon C Cheetham (3 out of 7 patents)

Core Competencies:

Medical Treatment

Therapeutic Agents

Pharmaceutical Mixture

Polypeptides

Thyroid Hormones

Dihydrodibenzisoquinolinediones

Isoquinoline Derivatives

Gene Expression

Sustained Release

Tetracycline Derivatives

Naphthyridinone Derivatives

4-Aminopyridines

84 patents: Sort by Forward Citations

1. 6617360 - Medical treatment (2003-09-09),

2. 6608025 - Human NESP55 polypeptides, polynucleotides and uses thereof (2003-08-19),

3. 6509493 - Method for producing atropic acid ethyl ester (2003-01-21),

4. 6500830 - Conversion of modification D to modification A of doxazosin mesylate (2002-12-31),

5. 6458842 - Liquid pharmaceutical compositions comprising thyroid hormones (2002-10-01),

6. 6353002 - Therapeutic agents (2002-03-05),

7. 6326496 - Process for preparing an intermediate in the production of paroxetine (2001-12-04),

8. 6312687 - Stabilized lactoperoxidase and glucose oxidase concentrate (2001-11-06),

9. 6251945 - Pharmaceutical mixture comprising a combination of a profen and other active compounds (2001-06-26),

10. 6239165 - Liquid pharmaceutical formulation containing zotepine (2001-05-29),

11. 6235281 - Use of anti-TNF antibodies as drugs for the treatment of disorders with an elevated serum level of interleukin-6 (2001-05-22),

12. 6225469 - Process for the preparation of 7-alkoxyalkyl-1,2,4-triazolo[1,5-A] pyrimidine derivatives (2001-05-01),

13. 6218405 - Heteroarylsulfonamide derivatives and pharmaceutical compositions containing them (2001-04-17),

14. 6215001 - Imidazole derivatives as therapeutic agents (2001-04-10),

15. 6201004 - Dioxino derivatives and their use as therapeutic agents (2001-03-13),

Knoll Aktiengesellschaft, headquartered in Ludwigshafen, Germany, specializes in the development and manufacturing of pharmaceutical compositions. The company focuses on innovative medical treatments and therapeutic agents, particularly in the areas of polypeptides and thyroid hormones. Its research encompasses a range of advanced compounds, including dihydrodibenzisoquinolinediones and isoquinoline derivatives, aimed at enhancing gene expression and improving patient outcomes in various medical conditions.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

84 Patents

#8 in Ludwigshafen

#687 in Germany

#9,044 in the World

Ludwigshafen, Germany

Knoll Aktiengesellschaft

Forward Citations = 1,217

147 inventors:

Hermann Bujard (6 out of 27 patents)

Joerg Rosenberg (6 out of 34 patents)

Manfred Gossen (6 out of 20 patents)

4. Alan Martin Birch (6 out of 7 patents)

5. Bruce Jeremy Sargent (6 out of 10 patents)

Please report any incorrect information to [email protected]

Loading…